Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The company’s stock surged to a record level after it disclosed clinical trial results seen as favorable, reinforcing expectations for continued growth in the global obesity treatment market.
THE APEX TIMES
THE APEX TIMES
Eli Lilly reported new Phase 3 results for its investigational triple-agonist retatrutide, showing substantial weight reduction plus clinically meaningful improvements tied to obesity-related conditions. The market reaction helped lift the stock on June 8.
THE APEX TIMES
A CMS pilot called the Medicare GLP-1 Bridge, starting July 1, 2026, is designed to study demand and costs for obesity drugs in the Medicare system. For Eli Lilly investors, the outcome could reshape expectations for how large the category can become.
THE APEX TIMES
Eli Lilly says its once-daily oral GLP-1 orforglipron, marketed as Foundayo, delivered larger A1C reductions in three pivotal type 2 diabetes trials, with weight-loss results emphasized most clearly in a head-to-head study against oral semaglutide.
THE APEX TIMES
The Nashville hospital operator says CHCP serves more than 8,000 students a year across campuses and online, and it will retain its chancellor and CEO after closing, which is still subject to approval.
THE APEX TIMES
The approval broadens HYMPAVZI (marstacimab-hncq) to include hemophilia patients with inhibitors and adds younger pediatric patients, reinforcing Pfizer’s push for non-factor, once-weekly prophylaxis.
THE APEX TIMES
At the American Diabetes Association’s 2026 Scientific Sessions, investors weighed new clinical updates from Eli Lilly, Pfizer, and Roche as the obesity drug market prepares for more entrants beyond the current leaders.
THE APEX TIMES
The deal gives J&J a proprietary Firelink platform designed to deliver targeted protein degraders, with an emphasis on KRAS-driven solid tumors.
THE APEX TIMES
The new Shockwave C2 Aero Coronary IVL device is designed to improve deliverability, lesion crossing, and balloon repositioning for procedures addressing hard, calcium-blocked arteries.
